Compare AU

Compare VEU vs. DRUG

Compare shares and ETFs on the ASX that you can trade on Pearler.

Vanguard All-World Ex-US Shares Index ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Vanguard All-World Ex-US Shares Index ETF (VEU) and the BetaShares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

VEU

DRUG

Popularity

Medium

Low

Pearlers invested

2,328

59

Median incremental investment

$1,200.00

$920.50

Median investment frequency

Monthly

Monthly

Median total investment

$4,500.25

$2,005.21

Average age group

> 35

26 - 35


Key Summary

VEU

DRUG

Strategy

Vanguard All-World ex-U.S. Shares Index ETF seeks to track the return of the FTSE All-World ex-US Index before accounting for fees, expenses, and tax. It aims to provide exposure to both the developed and emerging markets with the fund.

DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars.

Top 3 holdings

Nestle SA (1.31 %)

ASML Holding NV (1.00 %)

Taiwan Semiconductor Manufacturing Co. Ltd. (0.98 %)

CHF - SWISS FRANC (0 %)

AUD - AUSTRALIA DOLLAR (0 %)

DKK - DANISH KRONE (0 %)

Top 3 industries

Financials (17.94 %)

Industrials (12.80 %)

Consumer Discretionary (10.11 %)

Other (75.65 %)

Communication Services (33.53 %)

Health Care (24.23 %)

Top 3 countries

Japan (15.79 %)

United Kingdom of Great Britain and Northern Ireland (8.85 %)

China (8.33 %)

United States (71.71 %)

Switzerland (8.14 %)

Denmark (6.30 %)

Management fee

0.08 %

0.57 %


Key Summary

VEU

DRUG

Issuer

Vanguard

BetaShares

Tracking index

FTSE All-World ex US Index

Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD

Asset class

ETF

ETF

Management fee

0.08 %

0.57 %

Price

$95.65

$8.39

Size

$18.195 million

$183.750 million

10Y return

56.55 %

N/A

Annual distribution yield (5Y)

2.56 %

1.89 %

Market

ASX

ASX

First listed date

08/05/2009

08/08/2016

Purchase fee

$6.50

$6.50


Community Stats

VEU

DRUG

Popularity

Medium

Low

Pearlers invested

2,328

59

Median incremental investment

$1,200.00

$920.50

Median investment frequency

Monthly

Monthly

Median total investment

$4,500.25

$2,005.21

Average age group

> 35

26 - 35


Pros and Cons

VEU

DRUG

Pros

  • Higher exposure to AU market

  • Lower management fee

  • Higher distribution yield

  • Higher exposure to US market

  • Higher price growth

Cons

  • Lower exposure to US market

  • Lower price growth

  • Lower exposure to AU market

  • Higher management fee

  • Lower distribution yield

VEU

DRUG

Higher exposure to AU market

Lower exposure to AU market

Lower exposure to US market

Higher exposure to US market

Lower management fee

Higher management fee

Lower price growth

Higher price growth

Higher distribution yield

Lower distribution yield

Home